Abstract:Liver transplantation (LT) is the only available curative treatment for patients with end‐stage liver disease. Early allograft dysfunction (EAD) is a life‐threatening complication of LT and is thought to be mediated in large part through ischemia/reperfusion injury (IRI). However, the underlying mechanisms linking IRI and EAD after LT are poorly understood. Most previous studies focused on the clinical features of EAD, but basic research on the underlying mechanisms is insufficient, due, in part, to a lack of suitable animal models of EAD. There is still no consensus on definition of EAD, which hampers comparative analysis of data from different LT centers. IRI is considered as an important risk factor of EAD, which can induce both damage and adaptive responses in liver grafts. IRI and EAD are closely linked and share several common pathways. However, the underlying mechanisms remain largely unclear. Therapeutic interventions against EAD through the amelioration of IRI is a promising strategy, but most approaches are still in preclinical stages. To further study the mechanisms of EAD and promote collaborations between LT centers, optimized animal models and unified definitions of EAD are urgently needed. Because IRI and EAD are closely linked, more attention should be paid to the underlying mechanisms and the fundamental relationship between them. Ischemia/reperfusion–induced adaptive responses may play a crucial role in the prevention of EAD, and more preclinical studies and clinical trials are urgently needed to address the current limitation of available therapeutic interventions.

Emerging Role of Regulated Cell Death in Intestinal Failure-Associated Liver Disease

The Gut Microbiome and Intestinal Failure-Associated Liver Disease

The Role of Ischemia/Reperfusion Injury in Early Hepatic Allograft Dysfunction

Necroptosis in Inflammatory Bowel Disease and Other Intestinal Diseases

Cell Death in Liver Diseases: A Review

Advances in cell death - related signaling pathways in acute-on-chronic liver failure

A narrative review of the role of necroptosis in liver disease: a double-edged sword

Targeting cell death pathways in intestinal ischemia-reperfusion injury: a comprehensive review

Regulated cell death pathways in cardiomyopathy

Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications

The emerging role of regulated cell death in ischemia and reperfusion-induced acute kidney injury: current evidence and future perspectives

Understanding the molecular crossroads in acute liver failure: A pathway to new therapies

Targeting cell death in NAFLD: mechanisms and targeted therapies

The Role of NLRP3 Inflammasome Activation Pathway of Hepatic Macrophages in Liver Ischemia–Reperfusion Injury

Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations

New insights into regulatory cell death and acute pancreatitis

Research mechanisms of and pharmaceutical treatments for ferroptosis in liver diseases

Regulated cell death in chronic kidney disease: current evidence and future clinical perspectives

Inflammation drives pathogenesis of early intestinal failure-associated liver disease

The lipid basis of cell death and autophagy

Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions